The macrophage migration inhibitory factor (MIF) is a potent pro-inflammatory cytokine and regulates the anti-inflammator
Introduction
A number of experimental studies have led to the concept that macrophage migration inhibitory factor (MIF) functions as a physiological counter-regulator of glucocorticoid action within the immune system. In this role, MIF's position within the cytokine cascade is to act in concert with endogenous glucocorticoids to control the set point and the magnitude of the inflammatory response. 1 MIF also has several direct, pro-inflammatory roles in inflammatory diseases such as rheumatoid arthritis, MIF was originally described over 30 years ago as a Tlymphocyte-derived factor that inhibited the migration of peritoneal macrophages, 7 but it is now known that several other cell types, including macrophages themselves, are important sources of MIF. 8 MIF levels are elevated in the serum and synovial fluid of patients with rhemuatoid arthritis, 2, 9 and within the synovial joint MIF immunostaining can be localized to the synovial lining CD14 + macrophages and fibroblast-like synoviocytes. 2 Upon release MIF is directly pro-inflammatory by activating or promoting cytokine expression (TNF␣, 8, 10 IL-1␤, IL-2, 11 IL-6, 8, 12 IL-8 13 and IFN␥, 11, 14 ) , nitric oxide release, 15 matrix metalloproteinase (MMP) expression, 16, 17 and induction of the cyclooxygenase-2 (Cox-2) pathway. 18 MIF's capacity to induce sustained activation of the p44/p42 (ERK-1/2) MAP kinase pathway 18 and to inhibit p53-dependent apoptosis, 19, 20 also suggest that this mediator may play a key role in initiation of rheumatoid pannus.
We report herein the identification of a novel polymorphism in the human Mif gene that consists of a tetranucleotide CATT repeat located at position −794 of the Mif promoter. This promoter polymorphism is functionally significant in vitro, and analysis of a cohort of patients with rheumatoid arthritis indicates that this CATT repeat is associated with disease severity.
Results
Identification of a microsatellite repeat in the Mif promoter Genomic DNA from six normal volunteers and six rheumatoid patients was utilized for full sequencing of the Mif gene. Due to the high GC content of this gene, the analysis was carried out in four sections. Upon alignment of all 12 sequences, we identified a tetra-nucleotide CATT repeat polymorphism in the upstream promoter region at position −794 (Figure 1 ). We found individuals having 5, 6, 7 or 8-CATT repeat alleles in their sequences. Individuals were either heterozygous or homozygous for these alleles although no 7-CATT homozygotes were found in the normal population and no 8-CATT homozygotes were found in either population studied.
For rapid screening of the promoter-polymorphism, a fluorescently labeled reverse primer that was proximal to the tetranucleotide repeat units was designed in order to amplify a smaller PCR fragment (340-352 bp). This fragment then was analyzed using capillary electrophoresis on an ABI 310 Genetic analyzer. The DNA of individuals previously sequenced was used as a template to generate control DNA fragments in order to correlate the fragment size observed on the ABI 310 analyzer with the number of CATT repeats in the test samples. Accordingly, the four PCR product sizes were 340, 344, 348, and 352 bp in length, and these corresponded to 5, 6, 7, and 8-CATT repeats, respectively. The genotypes observed were 5,5, 5,6, 5,7, 6,6, 6,7,7,7, 5,8, and 6,8 . The 8,8 genotype was not seen in either the normal (n = 159) or patient (n = 184) populations and the 7,7 genotype was not seen in the normal population, but was observed in one patient within the rheumatoid arthritis group.
Distribution of Mif alleles in normal controls and rheumatoid arthritis patients
The distribution of the different Mif alleles in normal controls, mild rheumatoid arthritis and severe rheumatoid Genes and Immunity arthritis patients are shown in Table 1 . There was no deviation from Hardy-Weinberg equilibrium in normal controls (P = 0.69). The frequency of the 5,6,7 and 8 alleles was found to be 0.277, 0.607, 0.11 and 0.006 respectively.
The number of individuals carrying at least one 5-CATT allele decreases from 50.31% in the normal population to 31.65% in the severe rheumatoid arthritis population ( Table 1) . The difference between the severe rheumatoid arthritis patients and controls is statistically significant (P Ͻ 0.02). The cases and controls analyzed in this study were not closely matched for geographic and ethnic origin, other than being white Caucasian by selfreport. Hence the data must be interpreted with some caution. We therefore performed a comparison of specific genotypes between the mild and severe rheumatoid arthritis populations, all of whom were recruited in Wichita. Only white Caucasians were included in this analysis. As shown in Table 1 , the 5,5 genotype is observed in 9.5% of the patients with mild rheumatoid arthritis, but is significantly decreased to 1.3% in the patients with severe disease (P = 0.0252 by Fisher's exact test). The estimated relative risk (odd ratio) of having mild disease for homozygous 5,5 individuals with RA was 8.2 (95% CI 1.03-65.6). Therefore, homozygosity for the 5-CATT allele may be protective for the development of severe disease.
Effect of the CATT repeat polymorphism on MIF promoter activity
In order to investigate whether the CATT repeat polymorphism was associated with functional regulation of MIF expression, a gene reporter assay was developed and studied under defined conditions in vitro. Gene reporter assays have been widely employed to study transcriptional regulation, or as readouts to monitor transcription factor activation. 21, 22 Transfection of the Mif promoter-regulated luciferase constructs into Cos-7 cells, A549 cells, and CCD-19Lu cells was associated with strong basal promoter activity, as indicated by high luciferase production, when compared to control vector (pGL3-Basic) ( Figure 2 and data not shown). Promoter activity was increased by forskolin (an inducer of cAMP synthesis 23 ) and serum stimulation (Figure 3) , as well as phorbol ester stimulation (data not shown). In general, basal promoter activity was high in each of the cell lines tested when compared with negative (empty pGL3 vector) and positive (pRL-TK) controls, and these data appeared to correlate with the high level of endogenous MIF protein expression that was observed in these cell lines (data not shown). Of note, in each of the cell lines tested, the 5-CATT repeat MIF promoter construct showed significantly lower transcriptional activity when compared to the 6, 7, or 8-CATT repeat promoter constructs.
Discussion
The concept that polymorphisms in immune response genes contribute to the pathogenesis of certain human autoimmune/inflammatory disease has received increasing interest over the last several years. At present, very few gene polymorphisms have been shown to be functionally significant and to be of prognostic value in specific disease states. Previously defined examples include polymorphisms in TNF␣ and IL-1ra that have been shown to have certain prognostic significance in malaria and ischaemic heart disease respectively. 24, 25 Similarly, a number of polymorphisms in TNF␣ and IL-1␤ have been reported to be associated with rheumatoid arthritis severity. [26] [27] [28] The novel Mif gene polymorphism that we have identified is associated with reduced MIF promoter activity, and the presence of this genotype in the homozygous state appears to be associated with a reduced risk of severe rheumatoid arthritis.
MIF has been shown to promote TNF␣ secretion and to enhance IFN␥ induced nitric oxide secretion from macrophages. 8 In addition, MIF is an important autocrine regulator of macrophage, 8 T-cell 11 and fibroblast activation. 18 These data have led to numerous investigations of the potential role for MIF in chronic inflammatory conditions such as rheumatoid arthritis. MIF protein levels circulate in higher levels in serum of rheumatoid arthritis patients and cellular MIF expression is enhanced within the synovium.
2,9 Cultured synovial fibroblasts obtained from patients with rheumatoid arthritis secrete significant quantities of MIF spontaneously in culture, and secretion increased further following pro-inflammatory stimulation.
2 MIF stimulation of rheumatoid synovial fibroblasts results in increased expression of matrix metalloproteinases, 16 as well as the induction of phospholipase A 2 (PLA 2 ) and COX-2 expression. 29 Immunoneutralization of MIF activity in synoviocyte cultures also has been shown to inhibit IL-1␤ induced expression of COX-2 and PLA 2 mRNA. 29 The administration of a neutralizing anti-MIF antibody also delays the onset and decreases the severity of type-II collagen induced arthritis in mice 30 and profoundly inhibits the development of adjuvantinduced arthritis in rats. 31 Thus, there is considerable evidence implicating MIF in the pathogenesis of inflammatory arthritis.
We found a significant association between patients that are homozygous for the low expressing, 5-CATT allele and less aggressive rheumatoid disease. Only 1/79 (1.2%) patients with severe rheumatoid arthritis inherited this genotype, compared with 10/105 (9.5%) of patients with milder, non-progressive disease. This suggests that a genetic predisposition to low expression of MIF protects against persistent inflammation and/or joint destruction.
It is unknown at present which transcription factors may be involved in modulating the transcriptional effects of the polymorphic region, but the 5-CATT allele shows reduced responses in vitro to both serum and forskolin stimulation as well as reduced basal activity. A CATT repeated element also exists in the promoter of human granulocyte-macrophage colony-stimulating factor (GM-CSF), and is required for promoter activity. 32, 33 It has been shown that the nuclear factor YY1, 34 and more recently the factors AP-1 and SP-1, can from complexes with this region of the GM-CSF promoter. 35 Whether any of these same factors also influence the activity of the MIF CATT repeat remains to be studied.
The CATT-repeat region within the Mif gene contains several putative Pit-1 transcription factor binding sites. Pit-1 is a pituitary-specific transcription factor that is critical for the expression of pituitary hormones such as prolactin and growth hormone. 36 Of note, the anterior pituitary gland has been shown to be an important source of MIF in rodents, 3 and secretes MIF in response to physiological or infective stress. 37, 38 While there is some evidence that the hypothalamic-pituitary-adrenal (HPA) axis may play a role in the pathogenesis of rheumatoid arthritis in certain patients, 39 MIF does not appear to colocalize in the pituitary gland with the known expression pattern of Pit-1. 36, 38, 40 Since the initiation of these studies, a −173*G/C single nucleotide polymorphism (SNP) in the Mif gene promoter has been reported by Donn et al 41 and was shown to be associated with systemic-onset juvenile idiopathic arthritis (systemic-onset JIA). The possession of at least one −173*C allele was seen in 36.8% of patients with systemic-onset JIA compared with 20.3% of the normal population. 41 There is no information concerning the effect of this SNP on gene expression. A preliminary
Genes and Immunity analysis indicates that there is no evidence of positive linkage disequilibrium between the −173*C allele and the 5-CATT allele in either the control or rheumatoid arthritis populations (data not shown). Therefore, we think it unlikely that the 173*C allele is responsible for different promoter activities reported here. However, we have not specifically examined the role of the 173*C polymorphism in this regard.
TNF␣ is considered to be a critical effector cytokine in rheumatoid arthritis, and anti-TNF␣ therapy has emerged to have high efficacy in the treatment of this disease. 42 Of note, there is a close relationship between MIF and TNF␣. MIF appears to act as an important upstream regulator of TNF␣ expression. MIF promotes secretion of TNF␣ from macrophages and overrides the ability of glucocorticoids to suppress macrophage TNF␣ production. 43 Immunoneutralization of MIF also reduces circulating levels of TNF␣. 3 In a clinical setting, the analysis of MIF polymorphisms may prove useful as a prognosticator of rheumatoid disease, and could assist in the selection of interventional therapy. Our data also reaffirm the potential importance of MIF as a therapeutic target in rheumatoid arthritis and possibly other inflammatory disease.
Materials and methods
Patients DNA samples were obtained from the Wichita Rheumatic Disease Data Bank and were representative of Caucasian patients followed in a rheumatology practice since 1974. The rheumatoid arthritis patients were divided into two groups using the following criteria: (A) Severe (n = 79); mean age at onset 55 years, mean disease duration of 13 years, mean Larsen score rate of 4.0, mean RF titer of 339.24 and a mean HAQ score of 1.36. (B) Mild (n = 105); mean age at onset 45 years, mean disease duration of 15 years, mean Larsen score of 1.0, mean RF titer of 362.84 and a mean HAQ score of 0.93. Healthy Caucasian volunteers provided genomic DNA that was used as the normal control group (n = 159).
DNA extraction
DNA was extracted from whole blood using the G Nome kit (Bio 101 Inc, CA, USA) and from the buccal brushes using the Pure Gene Kit (Gentra Systems Inc, MN, USA).
Mif gene sequencing and polymorphism analysis
The Mif gene (GeneBank accession number: L19686) is located on chromosome 22q11.2. 44 The gene is 2167 bp and has 3 exons separated by 2 introns of 189 bp and 95 bp. Four sets of primers were used to span the entire gene ( Table 2 ). The PCR reaction consisted of 1× PCR buffer II (Perkin Elmer, CA, USA), 20 ng DNA, 1.5 mM MgCl 2 , 20 pmoles each of forward and reverse primers and 0.5 Units of Amplitaq Gold polymerase (Perkin Elmer-Applied Biosystems, CA, USA). The dNTP were used at a concentration of 0.2 mM except for set 3, where the 0.2 mM dNTP had 0.05 mM of 7-Deaza GTP in a 20 l PCR reaction. The PCR conditions were as follows: 95°C/12 min, followed by 40 cycles of 95°C/30 s, annealing temp (Table 2) /30 s, 72°C/60 s and 72°C/ 10 min. The PCR products were resolved using a 1% agarose gel stained with ethidium bromide.
The PCR products from six normal controls and six rheumatoid arthritis patients were sequenced using the Big Dye Terminator cycle sequencing ready reaction kit (Perkin Elmer-Applied Biosystems). The sequences from all four primer sets were compiled to represent the entire Mif gene and were compared in order to analyze differences between the rheumatoid arthritis group and the normal controls.
Rapid screening for CATT repeat polymorphism
The forward primer from set 1 was used with the reverse primer MIF-R −728 (5Ј-AATGGTAAACTCGGGGAC-3Ј). The reverse primer was fluorescently labeled with TET to allow detection of the PCR products using capillary electrophoresis. 45 The PCR conditions were 1× PCR Buffer II, 1.5 mM MgCl 2 , 0.2 mM dNTP, 0.75 pmoles of each primer, 1 ng DNA, 0.05 l AmpliTaq Gold polymerase in a 10 l PCR reaction. The PCR cycling conditions used were the same as described above except for annealing conditions of 53.8°C/30 s. One microliter of diluted PCR product was added to 12 l of deionized Figure 1 ). Forward primer: 5Ј-CTCGAGCTGCAGGAACCAATACCCAT-3Ј, reverse primer: 5Ј-AAGCTTGGCATGATGGCAGAAG GACC-3Ј. After complete sequencing, the promoter region was excised from the pCR2.1 vector and cloned into the XhoI/HindIII sites of the pGL3-Basic luciferase vector (Promega, WI, USA). This vector contains the cDNA encoding a modified version of firefly luciferase in the absence of eukaryotic enhancer or promoter elements. Luciferase constructs directly regulated by the MIF promoter, containing the 5, 6, 7, or 8-CATT polymorphism, were generated. Transient transfections were carried out using 3 l Fugene 6 (Roche, NJ, USA) and 1 g of DNA per well of a six-well plate as per manufacturers directions. Cell lines used included Cos-7 (monkey kidney fibroblast), A549 (human lung epithelium) and CCD-19LU (primary human lung fibroblast). Data were normalized in relation to an internal control of Renilla luciferase that was regulated by the Herpes simplex virus thymidine kinase promoter (pRL-TK vector -Promega, WI, USA). Subsequently, each transfection consisted of 800 ng of test DNA (MIF-promoter regulated Luciferase gene) combined with 200 ng of pRL-TK control vector DNA. Luciferase assays were measured using a TD-20/20 luminometer (Turner Designs, CA, USA) and the Dual Luciferase Reporter System (Promega). Basal promoter activity was determined by measuring luciferase activity 36 h after transfection. In some cases, cells were stimulated for the last 20 h of culture prior to measurement of promoter activity.
Genotype and statistical analysis
The data were analyzed using Genotyper 2.1 software (Perkin Elmer-Applied Biosystems). The relationship between the genotypes and disease status (normal, mild or severe) was examined using the chi-square test and Fishers' exact test. Gene reporter assays were repeated three to 10 times in duplicate. Data are presented as mean ± STDEV and compared by non-parametric MannWhitney U tests. Significance was defined as P Ͻ 0.05.
